Dermatology Disease Trials
NUCRYST initiated its second Phase 2 human clinical trial for NPI 32101 in October 2005. This double-blind, randomized, placebo-controlled study is expected to involve 28 clinical sites across the Canada and the United States. In total, 345 patients aged two to 17 years of age with mild to moderate eczema are planned to be treated for up to 12 weeks.
Patients in the Phase 2 clinical study are being treated with one of three cream formulations, either 1% or 2% concentrations of nanocrystalline silver in a proprietary NUCRYST formulation or with a placebo, which is the cream without any silver. The participating dermatologists will evaluate the effectiveness of topical nanocrystalline silver in improving the signs and symptoms of atopic dermatitis and its safety.
For more information regarding NUCRYST's ongoing clinical trials, please click here.